Business Context and Reporting Period
This Form 8-K Current Report is filed by Black Hawk Acquisition Corporation (BKHA), a Cayman Islands-based special purpose acquisition company (SPAC), for the reporting period of March 17, 2026. The filing discloses a material corporate development regarding the Company's proposed business combination target, Vesicor Therapeutics, Inc. ("Vesicor").
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, or liquidity metrics for Black Hawk Acquisition Corporation or Vesicor Therapeutics. The only financial data disclosed relates to the executive compensation agreement for Vesicor's new CEO:
- Base Salary: $48,000 annually (subject to revision if Vesicor raises a minimum of $5 million).
- Annual Bonus: Ad hoc, at the discretion of the Board of Directors.
- Severance: Up to two times the current base salary and target annual bonus, plus 24 months of health insurance premiums, in the event of termination without cause or for "Good Reason."
Material Changes
The primary material change reported is the leadership transition at Vesicor Therapeutics, effective March 17, 2026:
- Appointment of CEO: Dr. Michael Tolentino has been appointed as Chief Executive Officer of Vesicor.
- Role Change: Luo Feng, the former CEO of Vesicor, has assumed the position of Chief Scientific Officer.
- Employment Terms: Dr. Tolentino signed a 3-year employment agreement with annual renewal options, including specific non-compete and confidentiality provisions.
Guidance, Outlook, and Management Commentary
The filing does not contain financial guidance, revenue outlook, or specific management commentary regarding the financial performance of Black Hawk or Vesicor. However, it provides significant background on Dr. Tolentino's qualifications, highlighting:
- Over 20 years of experience in biotechnology, drug discovery, and clinical development.
- Key contributions to the development of Avastin and Bevasiranib.
- Founding roles at Acuity Pharmaceuticals (now OPKO Health), Panther Pharmaceuticals, Aviceda Therapeutics, and Avdarna Therapeutics.
- Expertise in AI-driven drug discovery through his work with Aikium, Inc.
Risks and Contingencies: The filing notes that the employment agreement includes termination provisions for cause, disability, or death. It also outlines a non-compete restriction lasting one year post-employment, subject to specific carve-outs and conditions regarding severance payment.
Investor Verification Checklist
- Verify the status of the proposed business combination between Black Hawk Acquisition Corporation and Vesicor Therapeutics.
- Confirm whether Vesicor has raised the minimum $5 million required to trigger a revision of Dr. Tolentino's base salary.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause," "Good Reason," and non-compete scope.
- Assess the impact of Dr. Tolentino's appointment on Vesicor's strategic direction and potential for future financing.
- Check for any subsequent filings regarding the completion or termination of the SPAC merger.